<DOC>
	<DOCNO>NCT00046891</DOCNO>
	<brief_summary>RATIONALE : Chemotherapy may cause memory loss , attention loss , problem make difficult patient think clearly . EGb761 may help maintain mental clarity patient undergoing chemotherapy . PURPOSE : Randomized clinical trial study effectiveness EGb761 preventing loss mental clarity woman receive chemotherapy newly diagnose breast cancer .</brief_summary>
	<brief_title>EGb761 Maintaining Mental Clarity Women Receiving Chemotherapy Newly Diagnosed Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine effectiveness EGb761 prevention chemotherapy-related cognitive dysfunction woman breast cancer . - Determine safety tolerability drug administer adjuvant chemotherapy patient . - Assess onset trajectory cognitive loss may occur chemotherapy patient . - Assess quality life cognitive role function patient treat drug . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord type chemotherapy ( doxorubicin/cyclophosphamide v doxorubicin/cyclophosphamide taxane v anthracycline-based chemotherapy v non-anthracycline-based chemotherapy ) , age ( 18 49 v 50 ) , menopausal status start therapy ( premenopausal v postmenopausal v unknown surgical reason ) , lymph node involvement ( 0-3 v 4 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral EGb761 twice daily . - Arm II : Patients receive oral placebo twice daily . Patients arm receive treatment beginning later start second course chemotherapy continue 1 month completion chemotherapy . Quality life cognitive function assess baseline , monthly chemotherapy , 1 , 6 , 12 , 18 , 24 month . Patients follow every 6 month 2 year . PROJECTED ACCRUAL : A total 220 patient ( 110 per treatment arm ) accrue study within 11 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose breast cancer Planned standard dos adjuvant chemotherapy without taxane PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Any status Performance status Eastern Cooperative Oncology Group ( ECOG ) 01 Life expectancy At least 6 month Hematopoietic No bleeding diathesis Hepatic serum glutamate oxaloacetate transaminase ( SGOT ) great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 1.5 time ULN Renal Creatinine great 1.5 time ULN Cardiovascular No arterial vascular disease Other Able complete questionnaire alone assistance No diabetes No dementia No diagnosis psychiatric disorder within past 5 year would preclude study compliance No significant comorbidity No known allergy ginkgo biloba Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent stem cell transplantation Chemotherapy No concurrent highdose chemotherapy Other More 6 month since prior EGb761 No concurrent antithrombotic therapy ( e.g. , daily aspirin anticoagulant ) Anticoagulants use central peripheral line maintenance ( i.e. , warfarin 1 mg/day heparin flush ) allow No concurrent doseintensive regimens No concurrent aspirin aspirinlike medicine ( e.g. , indomethacin , ibuprofen , antihistamine heparin warfarin [ except use ] ) No concurrent regimen expect cause thrombocytopenia No concurrent trazodone , monoamine oxidase inhibitor , thiazide diuretic ( e.g. , chlorothiazide , hydrochlorothiazide , indapamide , metolazone )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>